<DOC>
	<DOCNO>NCT00850512</DOCNO>
	<brief_summary>Study phase : Phase II Investigational product , dosage , route administration : Ibritumomab tiuxetan ( `` Zevalin ) compose murine IgG1 monoclonal antibody ( ibritumomab ) covalently bound chelate agent tiuxetan . To prepare active therapeutic agent [ 90Y ] -ibritumomab tiuxetan , antibody chelate Î²-emitter yttrium-90 chloride immediately intravenous administration . Treatment [ 90Y ] -ibritumomab tiuxetan precede infusion rituximab ( Rituxan , Mabthera ) order optimize biodistribution radiolabeled antibody deplete CD20 positive B-cells . Rituximab chimeric human/murine IgG1 monoclonal antibody . The Zevalin study regimen give infusion rituximab 250 mg/m2 ( biodistribution image dosimetry compulsory ) 185 MBq ( 5mCi ) [ 111In ] -ibritumomab tiuxetan Day 1 follow 7 9 day later single dose 14.8 MBq/kg ( 0.4 mCi/kg ) [ 90Y ] -ibritumomab tiuxetan , maximal dose 1184 MBq ( 32 mCi ) , precede 250 mg/m2 rituximab . Reference product , dosage , route administration : Not applicable Indication : stage II-IV diffuse large B-cell lymphoma ( DLBCL ) patient 4 cycle CHOP21-Rituximab ( CHOP21-R ) Study objective : Evaluation efficacy safety [ 90Y ] -ibritumomab tiuxetan , well assessment quality life Patient population : Patients 60 years-of-age DLBCL 4 cycle treatment CHOP21-R Study design : Prospective , multicenter , open-label study design treat patient sequential front-line treatment represent : 4 cycle CHOP21-R plus Zevalin Duration treatment : Four month CHOP21-R two treatment day one week apart follow 12-week safety period Zevalin Duration study : Estimated duration study 18 month Methodology : Primary efficacy parameter : Overall response rate complete response rate . Secondary efficacy parameter : Overall survival , disease-free survival , health-related quality life . Safety parameter : Vital sign , adverse event ( AEs ) , hematology , blood chemistry , immunoglobulin level Number study center : Planned total 10 study center Italy Total number patient , statistical rationale provide : Expected total approximately 55 patient . The final sample size base number event observe primary efficacy endpoint calculate sequential statistical model . Adverse event : AEs observe , mention upon open question and/or spontaneously report document . Planned start end recruitment : Start recruitment : 19/12/2006 . End recruitment : 04/11/2008 . Manufacturer ( ) investigational /reference product ( ) : Ibritumomab tiuxetan manufacture Biogen IDEC , San Diego , CA Cambridge , MA , USA . The isotopes yttrium-90 provide European supplier . There reference product study .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Subsequent Treatment With Zevalin ( Ibritumomab Tiuxetan ) Elderly ( More Than 60 Years ) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles CHOP21-Rituximab ( CHOP21-R ) Therapy</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>1 . Histologically confirm , Ann Arbor stage II , III , IV DLBCL accord REAL/WHO classification ( initial diagnosis make prior start CHOP21R therapy ) ; 2 . Central pathology review confirm DLBCL diagnosis CD20 positivity , evidence/evidence infiltration &lt; 25 % DLBCL bone marrow ; 3 . The first part treatment DLBCL must 4 cycle standard CHOP21 chemotherapy ( cyclophosphamide 750 mg/m2 , doxorubicin 50 mg/m2 , vincristine 1.4 mg/m2 maximum 2 mg day 1 , least 40 mg/m2/day prednisone Days 1 5 every three week ) combination rituximab ( 375 mg/m2 ) ; 4 . Complete remission ( CR ) , unconfirmed complete remission ( CRu ) , partial response , nonresponder accord International Workshop Response Criteria NHL describe Cheson et al ( 18 ) four cycle CHOP21R . CT scan neck , thorax , abdomen , pelvis PET total body must perform within 3 week last dose last course CHOP21R ; 5 . Patients 60yearsofage old time accrual ; 6. WHO performance status ( PS ) 0 2 within 1 week accrual ; 7 . Absolute neutrophil count ( ANC ) 1.5 x 109/L within 1 week accrual ; 8 . Hemoglobin ( Hgb ) 10 g/dL within 1 week accrual ; 9 . Platelets equal 150 x 109/L within 1 week accrual . 10 . Life expectancy 3 month longer 11 . Written inform consent obtain accord local guideline 1 . Presence malignancy history prior malignancy except nonmelanoma skin tumor stage 0 ( situ ) cervical carcinoma ; 2 . Prior radioimmunotherapy , radiation therapy , NHL therapy ; 3 . Presence gastric , central nervous system ( CNS ) , testicular lymphoma first diagnosis ; 4 . Histological transformation lowgrade NHL ; 5 . Known seropositivity hepatitis C virus ( HCV ) hepatitis B surface antigen ( HbsAg ) ; 6 . Known history HIV infection ; 7 . Abnormal liver function : total bilirubin &gt; 1.5 x ULN ALT &gt; 2.5 x ULN within 1 week accrual ; 8 . Abnormal renal function : serum creatinine &gt; 2.0 x ULN within 1 week accrual ; 9 . Nonrecovery toxic effect CHOP21R therapy ; 10 . Known hypersensitivity murine chimeric antibody proteins ; 11 . GCSF GMCSF therapy within two week ( four week pegylated ) prior screen laboratory sampling ; 12 . Concurrent severe and/or uncontrolled medical disease ( e.g. , uncontrolled diabetes , congestive heart failure , myocardial infarction within 6 month study , unstable uncontrolled hypertension , chronic renal disease , active uncontrolled infection ) could compromise participation study ; 13 . Treatment investigational drug le 4 week plan Day 1 nonrecovery toxic effect therapy ; 14 . Surgery less 4 week plan Day 1 nonrecovery side effect surgery ; 15 . Concurrent corticosteroid use reason except premedication case know suspected allergy contrast medium premedication potential side effect rituximab treatment ; 16 . Unwillingness inability comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>